BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management Sana Biotechnology, Inc. (SANA) | 6.3% New 13G [SEC] |
BVF Partners L.P. XOMA ROYALTY CORPORATION (XOMA)
Investment
Other | 43.3% +21.9 13D/A [SEC] On May 14, 2026, the Issuer waived the 61-day notice requirement to increase the Series X Beneficial Ownership Limitation, allowing the Reporting Persons to increase it to 45% of the Issuer's outstanding Shares. The Reporting Persons then converted all their Series X Preferred Stock at a conversion price of $4.03 per Share, resulting in BVF converting 2,313 Series X Preferred Stock for 2,313,000 Shares, BVF2 converting 1,506 Series X Preferred Stock for 1,506,000 Shares, Trading Fund OS converting 412 Series X Preferred Stock for 412,000 Shares, and Partners Managed Accounts converting 772 Series X Preferred Stock for 772,000 Shares. |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management Sana Biotechnology, Inc. (SANA) | 6.3% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.